S Losdat|S-M Chang|J M Reid - JoVE Visualize

Showing results (251-260 of 298) with videos related to

Pageof 30

Sort By:

International Journal of Radiation Oncology, Biology, Physics|September 1, 1996

Reirradiation of primary CNS tumorsG S Bauman, P K Sneed, W M Wara, et al.

Cancer|November 5, 1997

Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumorsF G Barker, S M Chang, S L Huhn, et al.

Proceedings of the National Academy of Sciences of the United States of America|December 24, 1996

Androgen-repressed phenotype in human prostate cancerH Y Zhau, S M Chang, B Q Chen, et al.

Biochemical Pharmacology|October 6, 1999

Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agentD L Walker, J M Reid, P A Svingen, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumorsH C Pitot, E A McElroy, J M Reid, et al.

Proceedings of the National Academy of Sciences of the United States of America|January 1, 1990

Fibroblast-mediated acceleration of human epithelial tumor growth in vivoJ L Camps, S M Chang, T C Hsu, et al.

Molecular and Cellular Biology|December 1, 1988

Expression of human adenosine deaminase in murine hematopoietic cellsJ W Belmont, G R MacGregor, K Wager-Smith, et al.

Global Health, Epidemiology and Genomics|September 29, 2018

The role of fathers in overweight prevention: an analysis of a Caribbean cohortJ A Smith, K D Rocke, S M Charles, et al.

Journal of Neuro-Oncology|February 24, 2001

A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent gliomaS V Rajkumar, J M Reid, P J Novotny, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyH C Pitot, R M Goldberg, J M Reid, et al.

Pageof 30

Showing results (251-260 of 298) with videos related to

Sort By:

Pageof 30

International Journal of Radiation Oncology, Biology, Physics|September 1, 1996

Reirradiation of primary CNS tumorsG S Bauman, P K Sneed, W M Wara, et al.

Cancer|November 5, 1997

Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumorsF G Barker, S M Chang, S L Huhn, et al.

Proceedings of the National Academy of Sciences of the United States of America|December 24, 1996

Androgen-repressed phenotype in human prostate cancerH Y Zhau, S M Chang, B Q Chen, et al.

Biochemical Pharmacology|October 6, 1999

Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agentD L Walker, J M Reid, P A Svingen, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumorsH C Pitot, E A McElroy, J M Reid, et al.

Proceedings of the National Academy of Sciences of the United States of America|January 1, 1990

Fibroblast-mediated acceleration of human epithelial tumor growth in vivoJ L Camps, S M Chang, T C Hsu, et al.

Molecular and Cellular Biology|December 1, 1988

Expression of human adenosine deaminase in murine hematopoietic cellsJ W Belmont, G R MacGregor, K Wager-Smith, et al.

Global Health, Epidemiology and Genomics|September 29, 2018

The role of fathers in overweight prevention: an analysis of a Caribbean cohortJ A Smith, K D Rocke, S M Charles, et al.

Journal of Neuro-Oncology|February 24, 2001

A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent gliomaS V Rajkumar, J M Reid, P J Novotny, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyH C Pitot, R M Goldberg, J M Reid, et al.

Pageof 30